{
  "retracted": false,
  "timestamp": 1591574400000,
  "updates": [
    {
      "timestamp": 1591609238164,
      "identifier": {
        "doi": "10.1186/s13063-020-04408-w"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1186/s13063-020-04341-y"
  },
  "journal": "Trials",
  "publisher": "Springer Science and Business Media LLC",
  "title": "Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)"
}
